| Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial A Musa, E Khalil, A Hailu, J Olobo, M Balasegaram, R Omollo, T Edwards, ... PLoS neglected tropical diseases 6 (6), e1674, 2012 | 191 | 2012 |
| Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial A Hailu, A Musa, M Wasunna, M Balasegaram, S Yifru, G Mengistu, ... PLoS neglected tropical diseases 4 (10), e709, 2010 | 167 | 2010 |
| Prevalence of malaria parasites in adults and its determinants in malaria endemic area of Kisumu County, Kenya R Jenkins, R Omollo, M Ongecha, P Sifuna, C Othieno, L Ongeri, ... Malaria journal 14, 1-6, 2015 | 132 | 2015 |
| Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study AM Musa, B Younis, A Fadlalla, C Royce, M Balasegaram, M Wasunna, ... PLoS neglected tropical diseases 4 (10), e855, 2010 | 129 | 2010 |
| Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial RO Phillips, J Robert, KM Abass, W Thompson, FS Sarfo, T Wilson, ... The Lancet 395 (10232), 1259-1267, 2020 | 99 | 2020 |
| Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial M Wasunna, S Njenga, M Balasegaram, N Alexander, R Omollo, ... PLoS neglected tropical diseases 10 (9), e0004880, 2016 | 93 | 2016 |
| Safety and efficacy of single dose versus multiple doses of AmBisome® for treatment of visceral leishmaniasis in eastern Africa: a randomised trial EAG Khalil, T Weldegebreal, BM Younis, R Omollo, AM Musa, W Hailu, ... PLoS neglected tropical diseases 8 (1), e2613, 2014 | 89 | 2014 |
| Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance … R Kimutai, AM Musa, S Njoroge, R Omollo, F Alves, A Hailu, EAG Khalil, ... Clinical drug investigation 37, 259-272, 2017 | 76 | 2017 |
| A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia E Diro, S Blesson, T Edwards, K Ritmeijer, H Fikre, H Admassu, A Kibret, ... PLoS neglected tropical diseases 13 (1), e0006988, 2019 | 75 | 2019 |
| Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan … BR Ogutu, KO Onyango, N Koskei, EK Omondi, JM Ongecha, GA Otieno, ... Malaria journal 13, 1-10, 2014 | 74 | 2014 |
| Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East … R Omollo, N Alexander, T Edwards, EAG Khalil, BM Younis, AA Abuzaid, ... Trials 12, 1-10, 2011 | 74 | 2011 |
| Probable post traumatic stress disorder in Kenya and its associated risk factors: a cross-sectional household survey R Jenkins, C Othieno, R Omollo, L Ongeri, P Sifuna, JK Mboroki, D Kiima, ... International journal of environmental research and public health 12 (10 …, 2015 | 61 | 2015 |
| Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase II … J Mbui, J Olobo, R Omollo, A Solomos, AE Kip, G Kirigi, P Sagaki, ... Clinical Infectious Diseases 68 (9), 1530-1538, 2019 | 52 | 2019 |
| Alcohol consumption and hazardous drinking in western Kenya—a household survey in a health and demographic surveillance site R Jenkins, C Othieno, L Ongeri, D Kiima, P Sifuna, J Kingora, R Omollo, ... BMC psychiatry 15, 1-10, 2015 | 49 | 2015 |
| Common mental disorder in Nyanza province, Kenya in 2013 and its associated risk factors–an assessment of change since 2004, using a repeat household survey in a demographic … R Jenkins, C Othieno, L Ongeri, P Sifuna, M Ongecha, J Kingora, D Kiima, ... BMC psychiatry 15, 1-12, 2015 | 43 | 2015 |
| Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial BT Nyang'wa, C Berry, E Kazounis, I Motta, N Parpieva, Z Tigay, ... The Lancet Respiratory Medicine 12 (2), 117-128, 2024 | 35 | 2024 |
| Tedium vitae, death wishes, suicidal ideation and attempts in Kenya-prevalence and risk factors R Jenkins, C Othieno, R Omollo, L Ongeri, P Sifuna, M Ongecha, ... BMC Public Health 15, 1-11, 2015 | 35 | 2015 |
| Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection W Hailu, T Weldegebreal, Z Hurissa, H Tafes, R Omollo, S Yifru, ... Transactions of the Royal Society of Tropical Medicine and Hygiene 104 (11 …, 2010 | 33 | 2010 |
| Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort … E Diro, T Edwards, K Ritmeijer, H Fikre, C Abongomera, A Kibret, ... PLoS neglected tropical diseases 13 (2), e0007132, 2019 | 32 | 2019 |
| Validation of two rapid diagnostic tests for visceral leishmaniasis in Kenya J Mbui, M Wasunna, M Balasegaram, A Laussermayer, R Juma, ... PLoS neglected tropical diseases 7 (9), e2441, 2013 | 22 | 2013 |
